Expression of CIP2A, bcl-2 and p63 in papillary thyroid cancer and their significances

Abstract

Objective To investigate the expression and significance of cellular inhibitor of protein phosphatase 2A (CIP2A), bcl-2 and p63 in papillary thyroid cancer (PTC). Methods Using immunohistochemistry to detect the expression of CIP2A, bcl-2 and p63 in 30 cases of nodular goiter (NG), 30 cases of thyroid adenoma (TA) and 57 cases of PTC [including classical PTC (cPTC) 20 cases, papillary microcarcinoma (PMC) 20 cases, follicular thyroid papillary carcinoma (FPTC) 7 cases]. Results In NG group, TA group and PTC group, positive rates of CIP2A were 0, 0 and 94.74% (54/57), respectively. The differences were statistically significant. In NG group, TA group and PTC group, positive rates of bcl-2 were 16.67% (5/30), 13.33% (4/30) and 85.96% (49/57), respectively. The differences were statistically significant. In each group, positive rates of p63 were 6.67% (2/30), 3.33% (1/30) and 5.26% (3/57), respectively, no significant difference among them. In PTC, expression of CIP2A and bcl-2 were significantly higher than in NG and TA (χ2= 105.56, P= 0.00; χ2= 58.95, P= 0.00). Furthermore, the expression of CIP2A and bcl-2 had correlation in PTC (r= 0.94, P= 0.00). The expression of CIP2A, bcl-2 and p63 had no significantly difference among all the PTC subtype(χ2 values were 2.02, 2.64, 1.85; all P > 0.05). The expression of CIP2A, bcl-2 and p63 was not associated with patients'age, sex, site, lymph node metastasis (all P > 0.05). Conclusions High expression of CIP2A and bcl-2 is associated with PTC, and the expression of CIP2A and bcl-2 has correlation in PTC. The expression of p63 has no correlation with PTC. Key words: Thyroid neoplasms; Papilloma; Cellular inhibitor of protein phosphatase 2A; bcl-2; p63